Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
32.37
+4.65 (16.77%)
At close: Jun 26, 2026, 4:00 PM EDT
33.01
+0.64 (1.98%)
After-hours: Jun 26, 2026, 7:27 PM EDT
COAG Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for COAG stock have an average target of 41.4, with a low estimate of 36 and a high estimate of 50. The average target predicts an increase of 27.90% from the current stock price of 32.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for COAG stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 |
|---|---|---|
| Strong Buy | 4 | 5 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $40 | Buy | Maintains | $40 | +23.57% | Jun 26, 2026 |
| Jefferies | Jefferies | Buy Maintains $39 | Buy | Maintains | $39 | +20.48% | Jun 8, 2026 |
| Evercore ISI | Evercore ISI | Buy Initiates $50 | Buy | Initiates | $50 | +54.46% | May 26, 2026 |
| Wedbush | Wedbush | Buy Initiates $42 | Buy | Initiates | $42 | +29.75% | May 26, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $36 | Buy | Initiates | $36 | +11.21% | May 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.06
EPS Next Year
-2.45
from -3.06
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.48 | -2.18 | |
| Avg | -3.06 | -2.45 | |
| Low | -3.59 | -2.69 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.